# Supplementary

Table 1. Distribution of antifungal susceptibility of 344 *Candida* species among 339 patients with candidemia during the study period

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Total isolates, n=344 (%) a | Caspofungin b | | | | Fluconazole b | | | | | Voriconazole b | | | | |
|  | S | I | R | missing | S | I | R | missing | S | | I | R | missing |
| *C. albicans,* n=182 (52.91) | 181(99.45) | 0 (0) | 0 (0) | 1 (0.55) | 172 (94.51) | 5 (2.75) | 1 (0.55) | 4 (2.20) | 180 (98.90) | | 0 (0) | 1 (0.55) | 1 (0.55) |
| *C. glabrata*, n=57, (16.57) | 29(50.88) | 2 (3.51) | 0 (0) | 1 (1.75) | NA | 53(92.98) | 1 (1.75) | 3 (5.26) | NA | | NA | NA | 34 (59.65) |
| *C. krusei,* n=0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA | NA | NA | 0 (0) | 0 (0) | | 0 (0) | 0 (0) | 0 (0) |
| *C. parapsilosis*, n=30 (8.72) | 30(100) | 0 (0) | 0 (0) | 0 (0) | 29 (96.67) | 0 (0) | 1 (3.33) | 0 (0) | 30 (100) | | 0 (0) | 0 (0) | 0 (0) |
| *C. tropicalis*, n=59 (17.15) | 59(100) | 0 (0) | 0 (0) | 0 (0) | 52 (88.14) | 3 (5.08) | 4 (6.78) | 0 (0) | 53 (89.83) | | 2 (3.39) | 4 (6.78) | 0 (0) |
| *C. guilliermondii,* n=1 (0.29) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | NA | NA | NA | 0 (0) | NA | | NA | NA | 0 (0) |
| *C. lusitaniae,* n=1 (0.29) | NA | NA | NA | 0 (0) | NA | NA | NA | 0 (0) | NA | | NA | NA | 0 (0) |
| *C. pelliculosa,* n=12 (3.49) | NA | NA | NA | 1 (8.33) | NA | NA | NA | 6 (50%) | NA | | NA | NA | 1 (8.33) |
| *C. famata,* n=1 (0.29) | NA | NA | NA | 0 (0) | NA | NA | NA | 0 (0) | NA | | NA | NA | 0 (0) |
| *C. rugosa,* n=1 (0.29) | NA | NA | NA | 0 (0) | NA | NA | NA | 0 (0) | NA | | NA | NA | 0 (0) |

Note: Data are presented as no. (%).

The MIC breakpoint for *in vitro* broth dilution susceptibility testing of *Candida* species to selected antifungal therapy after 24-hour incubation was based on CLSI M60-ED2:2020 Performance Standards for Antifungal Susceptibility Testing of Yeasts, 2nd Edition

Abbreviations: S, susceptible; I, intermediate; SDD, susceptible dose-dependent (or D); R. resistant r NA, not available

a the percentage of total isolates

b the percentage of each specific species

c MIC of caspofungin on *C. glabrata*: 2 strains reported MIC=0.25, but 25 strains reported S ≤ 0.25. According to the medical chart, 3 strains reported no AST results to caspofungin, 13 strains to fluconazole and 36 strains to voriconazole